Advanced Therapies in Ulcerative Colitis

BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (APPROVED BY HEALTH CANADA FOR IBD INDICATIONS)

Tremfya®/Janssen Johnson & Johnson Innovative Medicine/BioAdvance® (CD UC 2025)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Crohn’s Disease
Ulcerative colitis

CLASS

Monoclonal antibody interleukin (IL)-23 inhibitor

ACTION

Targets IL-23 protein receptor, which is one of the proteins responsible for inflammation. Blocking this receptor contributes to reducing inflammation